KURA - Kura Oncology, Inc.
IEX Last Trade
8.68
-0.070 -0.806%
Share volume: 9,639
Last Updated: Fri 27 Dec 2024 05:30:17 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$8.75
-0.07
-0.80%
Fundamental analysis
24%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
23%
Performance
5 Days
-0.89%
1 Month
-17.58%
3 Months
-54.47%
6 Months
-56.99%
1 Year
-36.76%
2 Year
-21.10%
Key data
Stock price
$8.68
DAY RANGE
$8.64 - $8.96
52 WEEK RANGE
$9.02 - $24.17
52 WEEK CHANGE
-$38.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Troy E. Wilson
Region: US
Website: kuraoncology.com
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kuraoncology.com
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.
Recent news